Print Page | Close Window

Xeloda Disappoints in Early Triple-Negative Breast

Printed From: TNBC Foundation
Category: TNBC Forums
Forum Name: Let's Talk About Chemotherapy
Forum Description: A place to discuss Chemotherapy
Printed Date: Jun 04 2020 at 12:01am
Software Version: Web Wiz Forums 12.01 -

Topic: Xeloda Disappoints in Early Triple-Negative Breast
Posted By: rstar
Subject: Xeloda Disappoints in Early Triple-Negative Breast
Date Posted: Dec 11 2018 at 12:05pm
However, they do state that in women with non-basal like phenotype, capecitabine did offer some advantage, with a 5-year DFS rate of 82.6% versus 72.9% among women with other phenotypes.
Seems like basal vs non basal phenotype plays the main role here." rel="nofollow -

Posted By: JenAus01
Date Posted: Dec 12 2018 at 2:40am
In reading through both trials from the US and Japan, there is a major difference in the  dose of Xeloda given to participants.    The US trial (as per the above article) is 1000 mg per day and the Japanese trail (Create-X) is 2500 mg per day.   Could this be the reason for the difference in results?  

As discussed in the US article shared above, agree that more research is needed to individualize treatment given there are many sub types of TNBC, but don't discount this treatment option if it applies to you until you talk to your oncologist.   


Posted By: 123Donna
Date Posted: Dec 12 2018 at 7:48am

Good observation!  

DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Posted By: JenAus01
Date Posted: Dec 13 2018 at 1:52am
A very observant friend with a chemistry background noticed the differences in doses.  but thank you Donna.  

Print Page | Close Window

Forum Software by Web Wiz Forums® version 12.01 -
Copyright ©2001-2018 Web Wiz Ltd. -